Recent Security Class Actions

39 Days left to seek lead plaintiff status.

The Complaint alleges that during the Class Period, Defendants disseminated materially false and misleading statements and/or concealed material adverse facts about the Company, causing Plaintiff and other shareholders to purchase Tandem’s securities at artificially inflated prices. On November 2, in an investment call and Form 8-K filing, the Company revised its 2022 forecast downward to the range of $800 to $805 million. Reasons stated for the scale back included increased competition in the diabetes care sector, complications due to the COVID pandemic, and macroeconomic factors such as inflation.

Tandem Diabetes Care Inc. Common Stock (NASDAQ: TNDM) Claim Form